TickerFacts.

Autolus Therapeutics plc (AUTL): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2021-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$117.69M
Year ended 2025-12-31
$112.63M
Trailing 12 months to 2026-06-30
+0.1%
3-year compound annual growth
$138.44M2016-09-30: $10.44M2017-09-30: $16.01M2018-09-30: $36.15M2019-12-31: $105.42M2020-12-31: $134.89M2021-12-31: $110.84M2022-12-31: $117.35M2023-12-31: $130.48M2024-12-31: $138.44M2025-12-31: $117.69M$117.69M
2016-09-30 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$117.69M-15.0%2026-03-27, From 2025-01-01
2024-12-31$138.44M+6.1%2026-03-27, From 2024-01-01
2023-12-31$130.48M+11.2%2025-03-20, From 2023-01-01
2022-12-31$117.35M+5.9%2024-03-21, From 2022-01-01
2021-12-31$110.84Mn/c2024-03-21, From 2021-01-01
2020-12-31$134.89M+28.0%2023-03-07, From 2020-01-01
2019-12-31$105.42Mn/a2022-03-10, From 2019-01-01
No annual figure between 2018-09-30 and 2019-12-31.
2018-09-30$36.15M+125.8%2020-03-03, From 2017-10-01
2017-09-30$16.01M+53.4%2020-03-03, From 2016-10-01
2016-09-30$10.44Mn/a2019-02-25, From 2015-10-01

R&D Expense at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Autolus Therapeutics plc (AUTL)2025-12-31$117.69M-15.0%
Recursion Pharmaceuticals, Inc. (RXRX)2025-12-31$475.27M+51.2%
Compugen Ltd (CGEN)2025-12-31$22.76M-8.3%
Black Diamond Therapeutics, Inc. (BDTX)2025-12-31$33.56M-34.6%
MeiraGTx Holdings plc (MGTX)2025-12-31$129.62M+8.5%
Vir Biotechnology, Inc. (VIR)2025-12-31$455.97M-10.0%
4D Molecular Therapeutics, Inc. (FDMT)2025-12-31$195.70M+38.5%
Champions Oncology, Inc. (CSBR)2026-04-30$9.08M+33.1%
Sutro Biopharma, Inc. (STRO)2025-12-31$166.42M-34.0%

Compare AUTL, RXRX, CGEN, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗